COMPASS
Clinical Proof
June 2012
What is IMOMA?
IMOMA – Instituto de Medicina Oncológica y Molecular de Asturias – is a private
institution created by Corporación Masaveu, Cajastur and Medicina Asturiana with
a clear mission: fight against cancer.
IMOMA aims to provide patients facing this disease best class and state-of-the-art
solutions to prevent and combat cancer. Its medical activity is based on three
mainstays: personalized treatments, integration of advances in molecular biology
in the clinical protocols and use of the latest radiotherapy techniques.
Starting activities in October 2011, the new IMOMA Radiotherapy Center is
equipped with a last generation LINAC: "TrueBeam™ STx powered by Novalis® ",
the result of cooperative work of Varian Medical Systems and Brainlab.
IMOMA has three state-of-the-art treatment planning systems: Philips Pinnacle 3, Varian Eclipse™ and Brainlab iPlan® . Thanks to those
valuable assets we perform cutting-edge techniques like IGRT, IMRT, VMAT (SmartArc® and RapidArc® ), frame and frameless image
guided Stereotactic Radiosurgery, 4D CT and respiratory gating, 6D correction using Brainlab’s robotic couch, and Stereotactic Body
Radiotherapy, allowing us to provide the best available radiotherapy treatments.
Clinical experience with COMPASS.
The Medical Physics Department relies on IBA Dosimetry technology, incorporating in our center several
quality control solutions as Blue Phantom2, StarTrack, MatriXX, OmniPro-I´mRT and COMPASS for
commissioning and further development of these complex techniques.
"From a physicist point of view, the process of commissioning and testing three different treatment planning
systems is very demanding. We must measure in all different conditions and make a thorough verification
program. The COMPASS system can be used in this task because it provides a very solid calculation
algorithm, requires very simple input data and the commissioning process is very fast and easy to use.”
Alberto Pérez-Rozos
Chief of the
Medical Physics Department
IMOMA – Centro Médico
de Asturias
[email protected]
"Verification of IMRT and VMAT treatments is performed with the COMPASS system, and fluencies are
measured with MatriXX. Thus, TPS dose calculation, integrity of data, and LINAC capabilities can be
verified in a single procedure.”
“The safety provided by COMPASS, along with time saving in the three mentioned verification points, plus
automated analysis of the histograms, has made COMPASS an indispensable tool in our clinical routine.
COMPASS allows us easy verification of any influence of uncertainty in dose volume histograms and 3D
dose distributions, serving also as an evaluation tool of our three TPS."
TrueBeam, Eclipse and RapidArc are trademarks or registered trademarks of Varian Medical Systems Inc. in the U.S. and/or other countries. Novalis and iPlan are trademarks or
registered trademarks by Brainlab AG in the U.S. and/or other countries. Pinnacle3 and SmartArc are trademarks or registered trademarks by Philips Healthcare in the U.S. and/or other countries.
RT-CA-E-Compass_CT_Oviedo-Rev.1-0612 | © IBA 2012 / All rights reserved
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Olivier Legrain, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
March 2012
The SoonChunHyang University Hospital in Cheonan, Korea, uses
the unique 3D plan verification system COMPASS to verify their
Novalis Tx treatments
The SoonChunHyang University Hospital took its first footstep as the only general hospital
in Chungcheonnamdo in 1982. The hospital currently operates 24 departments and 1000
beds with a crew of more than 1,300 people and 130 faculty members.
The Radiation Oncology Department started in 2000 and is equipped with the latest
medical facilities such as Novalis Tx treatment machines, Philips Big Bore CT and
PET-CT. 80 patients are treated with two LINACs per day. COMPASS is used specifically
for the Eclipse TPS for the Novalis Tx machine verification.
"COMPASS is the only system that can double check the beam data collection,
TPS beam modeling, dose calculation and also machine related errors.
COMPASS allows us to compare the 2D fluence segment by segment with more
detailed MLC movement information.
COMPASS checks accurately complicated plans for SRS, SBRT, IMRT and
VMAT patients at the Novalis Tx machine.
COMPASS is able to verify the QA result on real 3D patient CT images. It is
visual and uses DVH, 3D Gamma index, dose difference etc.
The SoonChunHyang
We are able to compare the discrepancies for different algorithm results in the
inhomogeneity area.
University Hospital
Chul Kee Min, Ph.D.
Clinical Assistant Professor
Chief Medical Physicist
Department of
Radiation Oncology
No need to calculate the phantom plan so we save a lot of time. We are able to
measure 10 patients during lunch time and do the reconstruction calculation
when we have time."
E-mail: [email protected]
RT-CA-E-COMPASS_CT_Cheonan_Rev.1-0312 | © IBA 2012 / All rights reserved
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
December 2011
Medanta – the Medicity, Haryana, India, replaced 2D patient plan
verification by COMPASS 3D dosimetry for IMRT and VMAT
Medanta – the Medicity was set up as a health care establishment in November, 2009.
The Division of Radiation Oncology became clinical in February 2010 and has established
cutting edge technology with two Linear accelerators, an Integrated Brachytherapy unit,
CT, MR and PET-CT simulation. The advanced techniques of radiation delivery, Volumetric
Modulated Arc therapy, 6-D correction with HEXA-POD, Monte Carlo calculation dose
engine in Monaco, COMPASS as a QA tool are a few of the highlights that have been
applied to daily clinical practice.
"We have commissioned COMPASS 3D dosimetry for Elekta INFINITY and Synergy S Beam Modulator
Linac. We have replaced 2D verification with COMPASS 3D dosimetry using combination of MatriXX
ion chamber array detector. Our observations on clinical commissioning and use are as follows.
Dr. Tejinder Kataria,
MD, DNB, CCST, FIMSA
Chairperson Radiation Oncology
Medanta Cancer Institute
Sector 38, Gurgaon,
– We have used COMPASS for various sites such as head & neck, prostate, esophagus, and breast
for IMRT and volumetric modulated arc therapy. We found that the results are well within limit and
good agreement between TPS & measured.
– COMPASS is a robust and precise tool for pre-treatment and plan verification of IMRT and volumetric
modulated arc therapy.
– COMPASS allows Radiation Oncologist and Physicist to do the IMRT and VMAT plan verification
on real patient's anatomy with tissue inhomogeneity correction and dose volume statistics.
– COMPASS reduced our medical physicist and treatment planning system time in generating QA plans
(as it does not need any QA plans on phantom), increased flexibility to verify accurately and decreased
time for more complex treatment modalities of IMRT and VMAT.
– There is no tool to check the accuracy of TPS calculated dose and its algorithm so far. Only COMPASS
verification software allows to cross check whether the TPS calculated dose is correct or not before
delivery to patient.
– COMPASS has an advanced dose calculation engine "collapsed cone convolution" that enabled us
to independently verify the beam model commissioning of different treatment planning systems.
– COMPASS is a fast and reliable 3D dosimetry verification system using with ion chamber array detector."
Haryana 122 001, India
Phone: +91 124-4141 414
Fax: +91 124-4834 111
[email protected]
www.medanta.org
Dr. Tejinder Kataria
Chairperson - Radiation Oncology
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
September 2010
COMPASS: 3D personalized plan verification.
Treatment safety, patient based, anatomically detailed: Radiation Oncologists can now verify the
actual delivered patient-in-dividual dose using the new COMPASS 2.0 platform.
The new IBA solution closes the missing link between personalized treatment planning and delivery
by giving Radiation Oncologists the power to verify treatment delivery not only generically as in
the past but individually for each patient.
With its unique approach, COMPASS is the only solution that veriies and displays dose independently
in each patient´s anatomy, bringing treatment verification to an entirely new oncologist-driven level.
Based on measurements of all irradiated fields and arcs, COMPASS calculates the delivered 3D dose
distribution utilizing the patient-individual anatomy and tissue inhomogeneity. Compared to
conventional cubic or cylindrical phantom based solutions which do not allow a patient-specific
verification, this approach provides far more accurate treatment verification. The COMPASS 3D dose
distribution can be compared to the TPS predicted dose with an intuitive and easy to use graphical
user interface: patient 3D dose overlay in sagittal, coronal and transversal views as well as
Dose-Volume-Histograms are available for an analysis on ROI level. The COMPASS Viewing Station
makes treatment verification and decision taking easy by bringing all relavant information onto the
oncologists´s desktop.
Klinik & Poliklinik für
Strahlentherapie und
Radioonkologie Göttingen
Germany
Dr. med. Dipl.-Phys.
Hilke Vorwerk
Senior Physician
"The COMPASS system enables me as a Radiation Oncologist to verify
the actual applied radiation therapy doses prior to treatment in a
patient-based 3D approach. The clinical relevance of underdose and
overdose areas can now be evaluated in relation to the patient individual
organs at risk and target volume based on clinical criteria, allowing me
to ensure safer treatment delivery.
Additional advantages of COMPASS are the 3 dimensional verification
of the real machine parameters that are integrated in the measured doses as
well as an independent check of the treatment planning system that provides
us with a higher confidence level for our patient treatments."
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
University Medical Center
Groningen
The Netherlands
Erik Korevaar, PhD
Medical Physicist
Department of Radiation
December 2011
"At the Radiotherapy Department of the University Medical Center
Groningen we replaced film dosimetry by COMPASS software with MatriXX
detector for pre-treatment verification in February 2009. We used the unique
COMPASS solution for verification of over 900 patient plans in the 36 months
after introduction. COMPASS was used for QA of IMRT treatment plans for
H&N, lung and prostate but also in cases like sarcomas and cervix cancer.
COMPASS is our standard QA tool for VMAT prostate plans as well.
Oncology
Tel.: +31 50 36 11 230
Fax: +31 50 36 11 692
[email protected].
All QA results were within clinical criteria which shows that we have a stable
linear accelerator, a reliable and well configured TPS and a stable QA system.
With COMPASS it was possible to avoid false non passing verifications which
appeared in some cases using film and which caused time consuming final
verification.
By irradiating QA plans on a regular basis and analyzing them with
COMPASS we were able to improve the control of critical IMRT parameters,
mainly the MLC calibration. This enables us to apply COMPASS as a pure
calculational verification for some routine cases, thus again reducing the time
needed for a single patient. An important reason to introduce the calculational
verification is to shorten the time until the start of treatment. Moreover, the
application of COMPASS measurement based verification for sample patients
at various moments in time allows us to further control stability of delivery.
With the increased flexibility in allocation of our physicist´s time, we are now
in the process of commissioning the new rotational modality VMAT which will
enable us to increase the number of patients treated with modulated modality.
We expect COMPASS to play a decisive role in the optimization and
verification of VMAT as well.”
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
January 2012
The Clinical Center Bayreuth, Germany, has been using COMPASS
clinically for all VMAT pre-treatment patient plan verifications
since mid 2010
The Clinical Center Bayreuth GmbH is the only hospital with
maximum medical care in the Upper Franconian region.
The clinic of radiation therapy is one of the most effective and
modern radiation therapy centers in Germany. Radiation therapy
treatments with modern high precision treatment machines allow
for a maximum of patient safety. The team of seven physicians,
five experts in medical physics, nine medical technical assistants
as well as nursing staff, medical secretaries and secretaries
ensure highest level patient-centered care.
“After initial installation of COMPASS in our department, we have been using the system in
a research phase for verification against our 2D plan verification solution. Since mid 2010 we
have been using COMPASS clinically for all our VMAT pre-treatment patient plan verifications.
We especially appreciate that COMPASS allows us to analyze the accuracy of the plan
delivery based on patient specific anatomy in 3D. Knowing dose errors related to the patient
anatomy is the basis to determine the clinical relevance of any discrepancies in the plan
verification.
Clinical Center Bayreuth
Germany
Dipl. Phys. Univ.
Mathias Dierl
COMPASS’ sophisticated dose calculation routine follows the proven approach implemented
in all treatment planning systems: Collapsed Cone calculations utilizing the patient specific CT
guarantee a very precise calculation of the delivered dose in 3D which is then verified
against the imported 3D dose from the TPS.
Beyond the routine plan verification COMPASS allows detection of spontaneous malfunction
of radiation delivery equipment as documented in a separate case study.”
Head of Medical Physics
Radiation Therapy
mathias.dierl@
klinikum-bayreuth.de
RT-CA-E-Compass_CT_Bayreuth-Rev.1-0212 | © IBA 2012 / All rights reserved
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com
COMPASS
Clinical Proof
January 2011
"Yashoda Hospitals being a leader in introducing high end technology is
really proud to be the first COMPASS user in India. Since March 2010 we
have been using the COMPASS to check all our IMRT & RapidArc plans.
With 100 RapidArc patients being treated every day we found COMPASS
as a comprehensive 3D QA tool because of the following reasons:
– Ability to independently check the accuracy of treatment plans from TPS
– Verification of individual arc segments precisely per rotation in
timely sequence
Sai Subramanian,
Chief Medical Physicist,
Yashoda Hospitals,
Hyderabad, India
– Accurate insight information about the treatment delivery, with delivered
dose distribution on planning CT to determine the clinical relevance
of dose discrepancies witah enhanced visuals
– Analysis of 3D gamma & dose difference on patient anatomy
Above all we could easily discuss our QA results with the Radiation
Oncologists as the results directly address the clinical consequences of
delivery."
RT-CA-E-Compass_CT_Yashoda-Rev.1-0212 | © IBA 2012 / All rights reserved
IBA Dosimetry GmbH Bahnhofstraße 5 | 90592 Schwarzenbruck | Deutschland | Tel.: + 49 9128 607 0 | Fax: + 49 9128 607 10
Register-Ger. Nürnberg, HR B 4262 | WEEE-Reg.-Nr. DE 65960409 | Geschäftsführer: Pierre Mottet, Rob Plompen
[email protected] | www.iba-dosimetry.com